Paul Kelly - Dec 17, 2021 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role: Director
Signature: /s/ Paul Kelly
Stock symbol: RLMD
Transactions as of: Dec 17, 2021
Transactions value $: $0
Form type: 4
Date filed: 5/26/2022, 06:43 PM
Next filing: Jan 5, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLMD	Stock Option (right to buy)	Award	$0	+182K	+155.25%	$0.00	300K	May 25, 2022	Common Stock	182K	$19.03	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.
F2	The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.

Content

The option grant was approved by the Board of Directors of the Company on December 17, 2021, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan (the "Plan") increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2022, at the 2022 Annual Meeting of the Company's shareholders.

The option vests in 16 equal quarterly installments, at 6.25% per quarter, commencing on March 17, 2022.